1. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration’s national program 
Elizabeth M. Oliva, Melissa L.D. Christopher, Daina Wells, Mark Bounthavong, Michael Harvey, Julianne Himstreet, Thomas Emmendorfer, Michael Valentino, Mariano Franchi, Francine Goodman, Jodie A. Trafton 
Journal of the American Pharmacists Association 
Volume 57, Issue 2, Pages S168-S179.e4 (March 2017)
DOI: /j.japh
Copyright © Terms and Conditions

2. Figure 1
Veterans Health Administration (VHA) Opioid Overdose Education and Naloxone Distribution (OEND) program timeline. The steps referred to in the timeline are described in detail in Table 1. In brief, the steps are: (1) identify clinical champion(s) for OEND implementation, (2) identify target patient populations, (3) garner support and prepare materials and resources and proposals and protocols, (4) obtain any necessary approvals to implement OEND, (5) train staff on OEND, (6) implement OEND, and (7) evaluate OEND.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

3. Figure 2
Veterans Health Administration (VHA) naloxone prescription options. The intramuscular and intranasal naloxone kits developed by VHA were replaced with corollary Food and Drug Administration–approved devices when they became available (e.g., the auto-injector replaced the intramuscular naloxone kit and the nasal spray replaced the intranasal naloxone kit).
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

4. Figure 3
Number of naloxone prescriptions dispensed and number of new prescribers per quarter.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

5. Appendix 1 VHA National OEND SharePoint site.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

6. Appendix 2 VHA Academic Detailing OEND Campaign Homepage.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

7. Appendix 3 VHA naloxone distribution by state (9/14/16).
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

8. Appendix 4
STORM Look-Up Report with Recommendations on an Example Actionable Patient.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions

9. Appendix 5 Pilot Naloxone Reversal Report.
Journal of the American Pharmacists Association  , S168-S179.e4DOI: ( /j.japh )
Copyright © Terms and Conditions